Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance - Quiz - MDSpire

Clinical Observation: Temporary Disease Management with Icotinib Following Osimertinib Resistance in Lung Adenocarcinoma with EGFR L858R/C797S and Absence of T790M

  • By

  • Shihang Song

  • Di Yao

  • Jinlong Liu

  • Wenjing Nie

  • Mengjia He

  • Jianqiao Zhang

  • Jing Zhao

  • July 20, 2026

Share

Original Source(s)

Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance

  • by Shihang Song, Di Yao, Jinlong Liu, Wenjing Nie, Mengjia He, Jianqiao Zhang, Jing Zhao

  • July 20, 2026

Related Content

Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer

Correction: Clinical benefit and safety of immunotherapy beyond progression in advanced and locally advanced lung cancer: a real-world cohort study

Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications